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The levels of human thyroperoxidase (hTPO) mRNA expression and the rates of hTPO mRNAwith alternatively spliced exons 10, 14, and
16 were analyzed in normal, benign, and malignant thyroid tissues (13 normal thyroid tissues, 9 adenomas, 4 papillary carcinomas, 11 follicular
variant of papillary carcinomas, 16 minimally invasive follicular carcinomas, 6 widely invasive follicular carcinomas) using a semi-quantitative
reverse-transcription polymerase chain reaction procedure. The level of hTPOmRNA decreased in the follicular variant of papillary carcinomas
and in minimally invasive follicular carcinomas and was more heterogeneous in the other pathological tissues than in normal tissues.
Based on the mean values recorded, the splicing of exons 10 and 16 increased by at least 50% in all the carcinomas, as well as in the benign
tissues in the case of exon 10. By contrast, no significant increase was observed in the splicing of exon 14 except in the case of the follicular
variant of papillary carcinomas.
In conclusion, the results of this study show that the splicing of hTPO increases in benign and malignant thyroid tissues. This event
might partly explain the decrease in both the quantity and the level of activity of hTPO observed in thyroid cancer due to the loss of stability
of the spliced isoforms. In addition, an increase in the alternative splicing of other mRNAs may contribute to the process of malignancy.
D 2004 Elsevier B.V. All rights reserved.Keywords: Thyroid; Cancer; Thyroperoxidase; mRNA splice variant
1. Introduction specific mRNAs [12–16] detected decreased or were virtu-Thyroperoxidase (TPO) is the key enzyme in thyroid
hormone synthesis. The human TPO (hTPO) gene consists
of 17 exons and 16 introns and spans about 150 kb. The
complete coding sequence of this enzyme is known [1–3],
and several single-spliced variants have been described:
TPO2 with exon 10 deleted [4], TPO3 with exon 16 deleted
[5], TPO4 with exon 14 deleted, and TPO5 with exon
8 deleted [6]. We have also showed the presence of multi-
spliced species, TPO2/3 with exons 10 and 16 deleted, TPO2/
4 with exons 10 and 14 deleted and TPO6 with exons 10, 12,
13, 14, and 16 deleted [6].
Several research groups have reported that the levels of
enzymatic activity [7–9], immune reactivity [10,11], and0925-4439/$ - see front matter D 2004 Elsevier B.V. All rights reserved.
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Variations in the splicing process are known to occur
during tumor development [17]. The consequences of alter-
native splicing range from switching the expression of a
protein on and off to the structural and functional diversifi-
cation of the protein products [18].
As hTPO in normal thyroid tissues undergoes a large
number of splicing events, it seemed to be worth investi-
gating whether the hTPO mRNA splicing process is affected
in differentiated thyroid carcinomas.
In the present study, we therefore investigated the total
hTPO mRNA levels and the rates of expression of the
various splice variants corresponding to TPO2, TPO3 and
TPO4 in diverse thyroid tumors.
2. Materials and methods
2.1. RNA isolation
Frozen specimens, 13 of which consisted of normal
thyroid tissue, 9 of adenomas, 4 of papillary carcinomas,
Table 1
PCR primer sequences
Primer Exon Position Sequence
PE9F 9 1392–1413 5V-GCAGTACGTGGGTCCCTATGAA-3V
PE11F 11 1876–1897 5V-TACAAGCATCCTGACAACATCG-3V
PE11R 11 1794–1773 5V-GCAGAACTCCCTCCACTCATTG-3V
PE12F 12 2111–2140 5V-TGCCCATGGATGCCTTCCAAGTCGGCAAAT-3V
PE13R 13 2209–2230 5V-AGCCACACTTGTCGTCTTGAGG-3V
PE15F 15 2577–2606 5V-CGGAGGCTTCGCAGGTCTCACCTCGACGGT-3V
PE15R 15 2573–2603 5V-TCGAGGTGAGACCTGCGAAGCCTCCGATCA-3V
PE17R 17 2881–2851 5V-TTTGCCTGTGTTTGGAAAAGAGTCGTACGG-3V
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minimally invasive follicular carcinomas, and 6 of wide-
ly invasive follicular carcinomas were used in these
experiments. Tissues were homogenized and prepared
using the Promega kit (SV total RNA isolation system)
according to the manufacturer’s instructions, and the
preparation was then treated with DNAse. The RNA
concentration was determined from the spectrophotomet-
ric absorption at 260 nm, and the RNA were aliquoted
and stored in water at  80 jC until further use. The
absorption ratio (260/280) was between 1.7 and 2.0 with
all the preparations.Fig. 1. Quantification of the total TPO mRNA levels recorded in each
histological group. N, normal thyroid tissue; A, adenoma; KPAP, papillary
carcinoma; KPVP, follicular variant of papillary carcinoma; KV-MIF,
minimally invasive follicular carcinoma, and KV-WIF widely invasive
follicular carcinoma. (A) scatter graph: the line represents the mean. (B)
The box-and-whisker plot shows quartiles: one quarter of the values lie
between the top whisker and the top of the box; one quarter lie above the
median line within the box; one quarter below the median line within the
box, and one quarter between the bottom of the box and the bottom
whisker. The box then extends from the 25th percentile to the 75th
percentile with a line at the median (the 50th percentile). *, p< 0.05; ***,
p< 0.001 (comparisons between normal tissues versus carcinoma tissues).2.2. Quantification of total TPO mRNA levels
To study the total TPO mRNA levels, RT was performed
using random hexamers and PCR reaction as described in
Ref. [19] with primers PE11F and PE13R. The volume of
the mixture was 100 Al and aliquots of 9 Al were taken from
the reaction mixture after different consecutive cycles and
loaded onto 2% agarose gel. After staining the products with
ethidium bromide, bands were detected and their intensity
quantified using an Image Station 440 (Kodak). The nor-
malized band intensities were plotted as a function of theFig. 2. Relative levels of the TPO mRNAs with exon 10 deleted. Reverse
transcriptions and PCR were performed as described in the Experimental
Procedures section. Aliquots of 9 Al were taken from the reaction mixture at
various cycles and analyzed with 2% gel agarose. The percentage levels of
hTPO mRNAwith exon 10 deleted were determined as described in Fig. 3.
The results obtained showed that hTPO with exon 10 deleted amounted to
29% (N), 49% (A), 60% (KPAP), 56% (KPVP), 61% (KV-MIF), and 63%
(KV-WIF).
Fig. 3. Calcul of the relative abundance of hTPO mRNA with exon 10
deleted in a follicular variant of papillary carcinoma (KPVP). A, After
analysis of the PCR products with 2% gel agarose (see Fig. 2) the bands
were quantified; ., hTPO with deletion of exon 10, o, hTPO without
deletion of exon 10. B, The amplification efficiency is given by the slope of
the line in a semi-logarithmic plot of the product accumulation versus the
number of cycles.
Fig. 4. Percentage levels of TPO mRNAwith exon 10 deleted determined in
each histological group. N, normal thyroid tissue; A, adenoma; KPAP,
papillary carcinoma; KPVP, follicular variant of papillary carcinoma; KV-
MIF, minimally invasive follicular carcinoma, and KV-WIF widely invasive
follicular carcinoma. (A) scatter graph: the line represents the mean; (B)
The box-and-whisker plot shows quartiles: one quarter of the values lie
between the top whisker and the top of the box; one quarter in above the
median line within the box; one quarter below the median line within the
box, and one quarter between the bottom of the box and the bottom
whisker. Then the box extends from the 25th percentile to the 75th
percentile with a line at the median (the 50th percentile). *, p < 0.05; ***,
p< 0.001 (comparisons between normal tissues versus carcinoma tissues).
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accumulated versus the number of cycles showed that the
efficiencies of the PCRs (as given by the slopes of the lines)
were the same with the different samples. Under these
conditions, the relative difference between the original
abundance of these different samples was taken to be 2n,
where n is the difference between the number of cycles
necessary to reach a threshold value. The threshold value
adopted here was the value in the exponential part of the
curve at which a statistically significant increase in the
fluorescence was detected. The normalization of samples
was carried out against total RNA in accord with recent
instruction [20].2.3. Quantification of the percentage levels of TPO mRNA
variants
Semi-quantitative RT-PCR was therefore performed in
order to measure the levels of hTPO mRNA in which exon
10, 14 or 16 was spliced out. RT was performed using
random hexamers and PCR procedure was performed as
follows: the reaction mixture (100 Al) consisted of 1 unit of
Taq DNA polymerase (Promega) (PE9F and PE11R) or 2
units of Fast Start Roche (0.8 Al) (PE12F and PE15R, or
PE15F and PE17R), Taq buffer, 1.5 mM MgCl2, 250 AM
dNTP, 10 Al of GC-rich solution, 0.3 AM oligonucleotide
primers (PE9F and PE11R, PE12F and PE15R, or PE15F
and PE17R). The reaction was run with the following
program: 6 min at 95 jC, then 35 cycles of 30 s at 94
jC, 30 s at 55 jC (PE9F and PE11R) or 30 s at 70 jC
(PE12F and PE15R, or PE15F and PE17R) and 1 min at 72
jC followed by a final extension for 7 min at 72 jC.
Aliquots of 9 Al were taken from the reaction mixture at
various cycles and analyzed with 2% gel agarose. The
products obtained were separated on 2% agarose gel. After
quantification, a correction due to the difference in product
size was applied as described previously [6] (1.73 for exon
10, 1.36 for exon 14, 1.73 for exon 16). The normalized
band intensities were plotted as a function of the number of
ysica Acta 1689 (2004) 134–141
Fig. 5. Relative levels of the TPO mRNAs with exon 14 deleted. Reverse
transcriptions and PCR were performed as described in the Experimental
Procedures section. Aliquots of 9 Al were taken from the reaction mixture at
various cycles and analyzed with 2% gel agarose. The percentage levels of
hTPO mRNAwith exon 14 deleted were determined as described in Fig. 3.
The results obtained showed that hTPO with exon 14 deleted amounted to
31% (N), 61% (A), 82% (KPAP), 76% (KPVP), 59% (KV-MIF), and 73%
(KV-WIF).
Fig. 6. Percentage levels of TPO mRNA with exon 14 deleted, as
determined in each histological group. N, normal thyroid tissue; A,
adenoma; KPAP, papillary carcinoma; KPVP, follicular variant of papillary
carcinoma; KV-MIF, minimally invasive follicular carcinoma, and KV-WIF
widely invasive follicular carcinoma. (A) scatter graph: the line represents
the mean; (B) The box-and-whisker plot shows quartiles: one quarter of the
values lie between the top whisker and the top of the box; one quarter in
above the median line within the box; one quarter below the median line
within the box, and one quarter between the bottom of the box and the
bottom whisker. The box then extends from the 25th percentile to the 75th
percentile with a line at the median (the 50th percentile). *, p< 0.05
(comparisons between normal tissues versus carcinoma tissues).
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lated versus the number of cycles showed that the efficien-
cies of the PCRs (as given by the slopes of the lines) were
the same with both of these species. Under these conditions,
the relative difference between the original abundance of
these two samples was taken to be 2n, where n is the
difference between the number of cycles necessary to reach
a threshold value [19]. The threshold value adopted here
was the value in the exponential part of the curve at which a
statistically significant increase in the fluorescence was
detected.
To determine whether the presence of a variant was really
dependent on its initial proportion within the cDNA popu-
lation, we performed PCR amplifications with various
quantities of the three cloned variants, pcDNA3-TPO2,
pcDNA3-TPO3, or pcDNA3-TPO4 with respect to
pcDNA3-TPO1 (3/1, 1/1, 1/3). In all the cases tested, the
ratio between the isoforms after their amplification corre-
sponded to their initial proportions.
2.4. Statistical analysis
The statistical analyses were performed using GraphPad
Prism version 3.0 for Macintosh. The rates of mRNA
expression were compared using one-way ANOVA withDunnett’s multiple post-tests (comparisons between normal
tissues versus carcinoma tissues).3. Results
3.1. Strategy
After the reverse transcription step, the cDNA was used
as a template for the PCR amplification procedure using the
series of primer pairs listed in Table 1. Each pair was chosen
so that a single exon was bracketed. In comparison with an
mRNA from which the relevant exon has been deleted, the
corresponding full-length mRNA amplifies a more slowly
migrating product. After amplification, the reaction products
were analyzed by migration on a 2% agarose gel.
3.2. Determination of hTPO mRNA levels
In the first set of experiments, in order to quantify the
total hTPO mRNA levels by RT-PCR, we chose primers
present in exons 11 (PE11F) and 13 (PE13R) (Table 1)
because this part of hTPO is practically never spliced out.
Splicing has only been observed in TPO6, and this
Fig. 7. Relative levels of the TPO mRNAs with exon 16 deleted. Reverse
transcriptions and PCR were performed as described in the Experimental
Procedures section. Aliquots of 9 Al were taken from the reaction mixture at
various cycles and analyzed with 2% gel agarose. The percentage levels of
hTPO mRNAwith exon 16 deleted were determined as described in Fig. 3.
The results obtained showed that hTPO with exon 16 deleted amounted to
39% (N), 53% (A), 72% (KPAP), 74% (KPVP), 75% (KV-MIF), and 66%
(KV-WIF).
Fig. 8. Quantification of percentage rates of TPO mRNA with exon 16
deleted in each histological group. N, normal thyroid tissue; A, adenoma;
KPAP, papillary carcinoma; KPVP, follicular variant of papillary carcino-
ma; KV-MIF, minimally invasive follicular carcinoma, and KV-WIF widely
invasive follicular carcinoma. (A) scatter graph: the line represents the
mean; (B) The box-and-whisker plot shows quartiles: one quarter of the
values lie between the top whisker and the top of the box; one quarter in
above the median line within the box; one quarter below the median line
within the box, and one quarter between the bottom of the box and the
bottom whisker. Then the box extends from the 25th percentile to the 75th
percentile with a line at the median (the 50th percentile). *, p < 0.05; ***,
p< 0.001 (comparisons between normal tissues versus carcinoma tissues).
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obtained here showed that the levels were relatively
homogenous between the various samples of normal
thyroid tissues tested (Fig. 1). The mean rate of expression
of hTPO transcripts in adenomas and papillary carcinomas
was similar to that observed in the normal tissue, although
the values obtained varied considerably (Fig. 1A). The
level of mRNA expression was significantly lower, 7–
785-fold in the case of the papillary carcinoma follicular
variant and 1–45-fold in the case of minimally invasive
follicular carcinomas (Fig. 1B). In five of the six widely
invasive follicular carcinoma samples studied, the TPO
mRNA levels were also greatly reduced.
3.3. Determination of the percentage rates of spliced
variants with exons 10, 14, and 16 deleted
Splicing of exons 8, 10, 14 and 16 has been previously
described in the literature. In our hands, it was possible to
quantify the percentage splicing of exons 10, 14 and 16,
but when it was attempted to quantify the spliced exon
8 using various pairs of primers, the results obtained were
never satisfactory or reproducible [6]. Although it was not
possible to obtain quantitative data supporting this assump-
tion, it seems likely that this splicing level increases in the
carcinoma in comparison with normal tissue (data not
shown).The primers used to study the deletion of exon 10 were
located in exon 9 (PE9F) and exon 11 (PE11R) (Table 1)
and led to a full size DNA of 403 bp and a smaller 233 bp
DNA corresponding to the spliced variant (Fig. 2). The band
intensities were then plotted as a function of a number of
cycle, an example is given in Fig. 3A. The semi-logarithmic
plot of the product accumulate versus the number of cycle
(Fig. 3B) showed that the efficiency of PCR (as given by the
slopes of the lines) were the same with the both species.
Under these conditions, the relative difference between the
original abundance of these two species is given by 2n
where n is the difference between the number of cycle
necessary to reach a threshold value. In the case presented in
Fig. 3A, the accumulation of PCR products were given by
the equations: y = 21.891100.1628x in the case of hTPO
without deletion of exon 10 and y = 19.492 100.1626 in the
case of hTPO with deletion of exon 10. With a threshold
value of 2 105 a difference of 0.34 cycle was obtained.
After a correction of 1.73 because of the difference of the
product size, hTPO with exon 10 deleted amounted to 56%
and hTPO with exon 10 amounted to 44%.
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recorded were significantly greater in those with the exon 10
spliced out (Fig. 4). The mean difference was 50% in the
adenomas, 70% in the papillary carcinomas, and 60% in the
papillary carcinomas follicular variants, minimally invasive
follicular carcinomas, and widely invasive follicular carci-
nomas. It is worth noting that greater heterogeneity was
obtained in the case of KV-WIF samples.
To study the deletion of exon 14, the primers used were
those located in exons 12 (PE12F) and 15 (PE15R), and this
yielded 493 and 362 bp products (Fig. 5). The level of
hTPO mRNAwith exon 14 deleted was significantly greater
only in the case of the papillary carcinoma follicular variants
(Fig. 6). The percentage levels of mRNA obtained in the
adenomas and the other carcinomas with exon 14 deleted
were approximately the same as in normal tissue. The great
variability observed in the case of minimally invasive
follicular carcinomas is worth noting.
Primers located in exons 15 (PE15R) and 17 (PE17F)
were used to quantify the percentage levels of hTPO mRNA
with exon 16 deleted, and this yielded 304 and 175 bp
products (Fig. 7).
In comparison with normal tissue, this percentage was
significantly higher in all the tumors apart from the adeno-
mas (Fig. 8). Based on the mean values obtained with the
various tumors, more than 55% of the mRNA had exon 16
deleted. Here again, as with the splicing of exon 10, the
heterogeneity of the results was greater in the case of KV-
WIF samples.4. Discussion
In the first part of this study, we quantified hTPO mRNA
in normal thyroid tissues, adenomas, and various carcino-
mas. The results obtained showed that in normal tissue,
adenomas and papillary carcinomas, the means were similar
but the levels of mRNAwere heterogeneous with variations
between the samples amounting to 117- and 35-fold in the
case of the adenomas and papillary carcinomas versus 3-
fold in that of normal tissues. With the other carcinomas, the
mRNA levels were practically always lower in all the
samples tested than in normal tissue, especially in the case
of the follicular variant of papillary carcinomas.
Many studies have been performed previously with a
view to determining the levels of expression of hTPO in
differentiated thyroid carcinomas [7–16,20]. The results of
all these studies except for one [21] showed that hTPO was
strongly underexpressed in carcinomas. These studies were
performed using Northern blotting, immunohistochemistry,
ELISA, or Western blotting techniques. All the analyses of
hTPO mRNA levels except for one [15] were performed
using non-quantitative methods.
The splicing of some exons can affect the folding of the
hTPO to a variable extent, depending of the splicing
location. The splicing of exons 8 and 10 leads to the rapiddegradation of the hTPO, while splicing of exon 14 or 16
leads to a decrease in the half-life of the enzyme but does
not affect its enzymatic activity or its intracellular trafficking
[6,22,23]. It is possible that the 50% or more increase in the
splicing of exons 10, 14, and 16 may lead to a considerable
decrease in the hTPO/mRNA hTPO ratio. In this case, it is
certainly possible to detect the mRNA of hTPO in carcino-
mas, but not the protein because of the rapid degradation it
undergoes.
Concerning the alternative splicing process, a great
increase was observed in the splicing of exons 10 and 16
in malignant tumors as well as in the benign tissues in the
case of exon 10. As we have previously described the
existence of multi-spliced transcripts, it is also possible that
the increase in the splicing of the various exons may lead to
an increase in the multi-spliced transcripts [6]. It was not
possible here for technical reasons to quantify the rate of
splicing of exon 8 corresponding to TPO5 [6]. Some of the
results obtained do, however, seem to indicate that an
increase in the splicing levels occurred in this exon (data
not shown).
In some cases, we noted some heterogeneity in the
percentage rate of splicing events in the same specific form
of the disease (for example, in the rate of splicing of exon
10 and exon 16 in KV-WIF or exon 14 in KV-MIF).
Differences in the percentage rate of splicing events in a
specific tumor type either indicate that a change has
occurred in some particular samples regardless of the
tumor type, or indicate the existence of sub-populations
in this specific tumor type. In both cases, the results will
be heterogeneous. However, our analysis of all the results
obtained showed that the hTPO splicing increased on the
whole in carcinomas.
SR proteins play decisive roles in alternative splice site
selection and certainly the relative levels and rates of
activity of the members of this family of proteins may be
one of the main regulatory factors involved in the alternative
splicing mechanism [24]. It would therefore be most inter-
esting to determine the pattern and the concentration of the
various SR proteins in normal tissue and in carcinomas of
various kinds. Since a large number of genes produce
alternative transcripts which, when transcribed, lead to
protein products with altered structures and functions,
changes in these alternative splicing processes may be one
of the factors contributing to the development of some
forms of cancer. In some tissues, it has been established
that many cancer-associated genes such as WT1 and CD44
are alternatively spliced, and alternative splicing processes
may therefore be one of the causal steps responsible for the
development of some types of cancer [17]. Here we ob-
served that the alternative splicing of hTPO increased in the
thyroid carcinomas tested. The extent of the increase
depended on the exon. This modification will certainly lead
to a decrease in the quantity of hTPO and its rate of activity
in thyroid cancer. However, it is not yet clear whether the
increase in the percentage rates of the spliced variants of
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tumorigenesis or whether these variants were more directly
involved in the actual process of thyroid tumor develop-
ment. The exact role of the spliced form of hTPO in the
development of thyroid tumors cannot be easily explained.
First, it is difficult to understand how the splicing variant
may be directly involved in the development of thyroid
tumors. Recent studies have suggested that splicing alter-
ations might be widespread in human cancer [25]. However,
a decrease in the activity of hTPO leads to an iodide
organification defect and to congenital goiter. In this case,
it is possible that prolonged stimulation by TSH may result
in the occurrence of thyroid carcinoma [26].
De Micco et al. [11,27,28] have shown the existence of a
correlation between the pattern of immunohistochemical
labeling obtained on hTPO with a monoclonal antibody
directed against hTPO (mAb47) and the malignancy of the
carcinoma. The mAb47 is directed against a linear sequence
located in a region corresponding to exon 12 (Lys713–
Ser723) [29]. In normal thyroid tissue, exon 12 is never
spliced except in TPO6 [6]. This isoform is present in very
low levels and we did not observe any increase in the
alternative splicing of exon 12 in the carcinomas (data not
shown). The results obtained with mAb47 were therefore
certainly due to the quantitative decrease in hTPO rather
than to an antigenic change in the protein. This conclusion is
also supported by data published by Czarnocka et al. [10]
showing that hTPO expressed in thyroid cancers displayed
similar epitopes to that of hTPO from Grave’s disease tissue.
In conclusion, we investigated normal thyroid tissues,
adenomas and carcinomas to determine how the hTPO
levels and alternative splicing rates were affected by the
disease. The levels of hTPO were found to decrease in
practically all the carcinomas tested as compared to the
normal tissues, and the percentage rates of hTPO mRNAs
showing alternative splicing increased in the carcinomas,
especially in exons 10 and 16.Acknowledgements
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